Abiomed (NSDQ:ABMD) is slated to win a reimbursement code for procedures involving its Impella heart pump, according to analysts at Piper Jaffray.
In a summary of recent editorial panel decisions, the American Medical Assn. revealed that the panel approved the Society for Cardiovascular Angiography and Interventions’ proposal for the reimbursement code, according to theflyonthewall.com.
The code will help push utilization rates for the Impella device higher, the Piper analysts noted, maintaining their “overweight” rating on Abiomed shares, website.
Sign up to get our free newsletters delivered straight to your inbox
ABMD shares were trading at $21.25 as of about 12:30 p.m. today, up 2.3%.
Abbott split spreads uncertainty?
Abbott’s (NYSE:ABT) plan to spin out its research pharmaceuticals business – including its blockbuster Humira anti-inflammatory drug – is creating uncertainty among investors, according to Medill Reports, but ABT shares hit a 52-week high not long ago – not to mention today, when it logged another at $57.60 – and is up about 8% since the plan was floated to investors last fall. Read more
Boston Scientific re-inks Lumenis urological laser deal
Boston Scientific (NYSE:BSX) re-inked its deal with Lumenis, signing a 5-year, exclusive contract to distribute Lumenis’ holmium laser fibers for urological devices in the U.S. Read more
Pseudo-exit: JumpStart’s MAX Endoscopy clings to life
Cleveland’s JumpStart economic development group hung on long enough for an exit of sorts for MAX Endoscopy, even after its original investors decided to pull the plug. Read more
Analogic declares dividend
Analogic (NSDQ:ALOG) declared a quarterly dividend of 10 cents per share, payable March 29. Read more
Osprey Medical launches Aussie IPO
Osprey Medical, which is developing a catheter-based device to reduce contrast-induced nephropathy by re-capturing the dye used during angiographies, is looking to raise about $21 million U.S. in an underwritten public offering Down Under, far less than more-ambitious and still-under-water IPOS (paid) by other med-tech makers like GI Dynamics (ASX:GID) and its $86 million Aussie IPO. Read more
Cleveland Clinic spins out pre-op software firm
Cleveland Clinic Innovations spun out a new startup, Custom Orthopaedic Solutions, which is developing OrthosVis software to import CT scans and generate a 3D model for docs to examine ahead of surgeries. Read more
Medivo buys WellApps
Health IT firm Medivo acquired GI Monitor developer WellApps for an undisclosed amount. Read more
Titan Medical announces $3M offering
Titan Medical (CVE:TMD) hopes to raise $3 million in an offering of about 2 million shares priced at $1.51 apiece. Read more
Analysts’ ups and downs
